Terminated trial tests cancer drug for rare, aggressive tumors
NCT ID NCT04042714
Summary
This study tested whether an existing cancer drug called TAS-102 could help patients with a rare, aggressive form of neuroendocrine cancer that starts outside the lungs. The trial enrolled 14 patients who had already tried platinum-based chemotherapy, aiming to see if TAS-102 could slow tumor growth and extend survival. The study was terminated early, and results were not widely reported.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-GRADE EXTRA PULMONARY NEUROENDOCRINE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor Scott and White University Medical Center,
Dallas, Texas, 75246, United States
Conditions
Explore the condition pages connected to this study.